Vascular Therapies Appoints John McDermott as Chief Executive Officer


January 10, 2019—Vascular Therapies, Inc. announced the appointment of John McDermott as the Company’s Chief Executive Officer. Mr. McDermott previously served as Chief Executive Officer of Endologix, Inc., President of Bard Peripheral Vascular, and Chief Operating Officer at Impra.

Vascular Therapies is a privately held clinical-stage biotechnology company focused on improving outcomes for patients with advanced kidney disease. The company is developing a sirolimus formulation for local, perivascular drug delivery to address vascular anastomosis failure. This investigational therapy is currently being evaluated in phase 3 randomized clinical trial, which is being performed under a Special Protocol Assessment. The drug development program has received Fast Track status from the FDA and sirolimus has Orphan Drug status for the dialysis vascular access indications in the United States and European Union, advised the company.

Bob Croce, Chairman of the Board of Directors of Vascular Therapies, commented in the announcement, “We are very pleased to welcome John as our Chief Executive Officer. John has nearly 30 years of experience in the vascular industry and has led the development and successful commercialization of multiple ground-breaking new technologies. Dr. Sriram Iyer, the founder of Vascular Therapies, has done an excellent job leading the company since inception and will continue as its Chief Scientific Officer.”


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.